FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
This article was originally published in Pharmaceutical Approvals Monthly
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
You may also be interested in...
FDA Expects Sharp Drop In Drug Applications This Year
Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class